Publications by authors named "Lucia Marquez-Mosquera"
Introduction: Inflammatory bowel disease (IBD) is usually diagnosed when symptomatic. Prognosis and evolution of preclinical IBD is largely unknown. However, colorectal cancer screening programs (CRCSP) detect a subset of IBD patients with no symptoms.
View Article and Find Full Text PDFThe human gut includes plasma cells (PCs) expressing immunoglobulin A1 (IgA1) or IgA2, two structurally distinct IgA subclasses with elusive regulation, function, and reactivity. We show here that intestinal IgA1+ and IgA2+ PCs co-emerged early in life, comparably accumulated somatic mutations, and were enriched within short-lived CD19+ and long-lived CD19- PC subsets, respectively. IgA2+ PCs were extensively clonally related to IgA1+ PCs and a subset of them presumably emerged from IgA1+ precursors.
View Article and Find Full Text PDFArticle Synopsis
- Ustekinumab is approved for treating ulcerative colitis (UC), and this study evaluated its long-term effectiveness and tolerability in real clinical settings.
- In a multicenter analysis of 620 UC patients, 25% discontinued treatment, with baseline anemia, steroid use, and severe disease linked to higher discontinuation rates.
- At 16 weeks, 40% of patients were in steroid-free remission, and treatment was generally safe with no adverse effects on other conditions, indicating good long-term durability for difficult-to-treat cases.
Background: Ulcerative proctitis (UP) can have a milder, less aggressive course than left-sided colitis or extensive colitis. Therefore, immunosuppressants tend to be used less in patients with this condition. Evidence, however, is scarce because these patients are excluded from randomised controlled clinical trials.
View Article and Find Full Text PDFBackground: some patients with inflammatory bowel disease (IBD) treated with antiTNF develop drug-induced psoriasis (antiTNF-IP). Several therapeutic strategies are possible.
Aims: to assess the management of antiTNF-IP in IBD, and its impact in both diseases.
Article Synopsis
- A study was conducted to evaluate the effectiveness and safety of ustekinumab and vedolizumab in treating complex perianal fistula in patients with Crohn's disease.
- Out of 155 patients analyzed, ustekinumab achieved a remission rate of 54%, while vedolizumab had a remission rate of 46%, with some patients relapsing during the follow-up period.
- Both medications exhibited mild adverse events and showed favorable safety profiles, indicating their potential effectiveness in managing this condition.
Article Synopsis
- Markers for personalized treatment options for patients with inflammatory bowel diseases (IBD) remain unidentified, prompting a study on real-life treatment trends.
- The study analyzed data from 10,009 patients from the ENEIDA registry, revealing that anti-TNF drugs were the most commonly used first-line treatments, but their usage declined over time in Crohn's disease (CD) while remaining stable in ulcerative colitis (UC).
- Despite exploring Machine Learning for treatment pattern prediction, researchers found that these models were ineffective, indicating distinct treatment approaches for CD and UC and highlighting the rising importance of drugs like ustekinumab and vedolizumab.
Article Synopsis
- The study aimed to evaluate the effectiveness of early medical prophylaxis versus waiting for endoscopy findings in preventing postoperative recurrence (POR) in patients with Crohn's disease after ileocaecal resection (ICR).
- Out of 346 patients, those receiving early prophylactic treatment (Cohort 1) had significantly lower endoscopic recurrence rates compared to those who only received treatment based on endoscopy results (Cohort 2).
- While both groups did not show significant differences in severe endoscopic POR or time to surgical recurrence, the proactive group had a lower treatment burden when using immunomodulators.
Article Synopsis
- Chronic gut inflammation in Crohn’s disease (CD) is linked to increased oxidative stress and decreased catalase (CAT) enzyme activity.
- A study analyzed data from 598 CD patients and 625 healthy controls, identifying significant SNPs in the CAT gene associated with CD and the severity of the disease in smokers.
- Findings indicated that reduced CAT activity in white blood cells of CD patients is due to low protein levels from downregulated gene expression, suggesting a connection between CAT SNPs and the risk of developing CD.
Background: Vedolizumab is a humanized monoclonal antibody targeting the αβ integrin used for the treatment of ulcerative colitis. Few biomarkers related to vedolizumab response have been identified. The aim of this work was to assess whether baseline circulating CD4 and CD8 memory T-lymphocyte subpopulations could help to identify patients with response to vedolizumab treatment in ulcerative colitis.
View Article and Find Full Text PDFBackground And Aims: Crohn's disease [CD] can develop penetrating complications at any time during the disease course. Enterocutaneous fistulae [ECF] are disease-related complications with an important impact on quality of life. Our aim was to describe the outcomes of this complication, including its medical and/or surgical management and their temporal trends.
View Article and Find Full Text PDFBackground: Anti-tumor necrosis factor agents (anti-TNFs) are efficacious at preventing the postoperative recurrence (POR) of Crohn disease, as demonstrated in 2 randomized controlled trials. However, real-life data for infliximab or adalimumab in this setting are scarce. Our aim was to assess both the efficiency of anti-TNFs at preventing early POR of Crohn disease in clinical practice and the associated risk factors for POR.
View Article and Find Full Text PDFBackground: In APPRECIA trial, Crohn's disease (CD) patients undergoing intestinal resection were randomized to postoperative adalimumab (ADA) or azathioprine (AZA).
Aims: To evaluate health-related quality of life (HRQoL) in APPRECIA trial.
Methods: HRQoL was evaluated using disease-specific shortened Spanish version of the IBDQ (SIBDQ-9) and generic European Quality of Life-5 Dimensions (EQ-5D) questionnaires, completed at baseline and at weeks 24 and 52.
Background And Aims: Postoperative recurrence of Crohn's disease [POR-CD] is almost certain if no prophylaxis is administered. Evidence for optimal treatment is lacking. Our aim was to compare the efficacy of adalimumab [ADA] and azathioprine [AZA] in this setting.
View Article and Find Full Text PDF